1. Home
  2. Upgrades
  3. Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise

Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise

5
0

Shares of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) climbed in early trading on Monday, after several analysts raised their forecasts.

The stock seems poised for a recovery due to the Austedo franchise, the improved positioning of the U.S. generics business and a better capital structure, according to Piper Sandler.

The Teva Pharmaceutical Industries Analyst: David Amsellem upgraded the rating for Tel Aviv-Yafo, Israel-based Teva from Neutral to Overweight, while raising the price target from $12 to $19.

Check out other analyst stock ratings.

The Teva Pharmaceutical Industries Thesis: The Austedo franchise is well positioned due …

Full story available on Benzinga.com

Visited 5 times, 1 visit(s) today